Clinuvel Pharmaceuticals Ltd

AU:CUV Australia Biotechnology
Market Cap
$303.07 Million
AU$489.46 Million AUD
Market Cap Rank
#13786 Global
#179 in Australia
Share Price
AU$9.75
Change (1 day)
-0.81%
52-Week Range
AU$9.44 - AU$13.70
All Time High
AU$44.55
Categories
Companies in Australia Biotechnology
About

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more

Clinuvel Pharmaceuticals Ltd (CUV) - Net Assets

Latest net assets as of December 2025: AU$249.02 Million AUD

Based on the latest financial reports, Clinuvel Pharmaceuticals Ltd (CUV) has net assets worth AU$249.02 Million AUD as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$269.70 Million) and total liabilities (AU$20.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$249.02 Million
% of Total Assets 92.33%
Annual Growth Rate 11.65%
5-Year Change 143.89%
10-Year Change 1250.24%
Growth Volatility 77.3

Clinuvel Pharmaceuticals Ltd - Net Assets Trend (2000–2025)

This chart illustrates how Clinuvel Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Clinuvel Pharmaceuticals Ltd (2000–2025)

The table below shows the annual net assets of Clinuvel Pharmaceuticals Ltd from 2000 to 2025.

Year Net Assets Change
2025-06-30 AU$240.81 Million +18.62%
2024-06-30 AU$203.01 Million +23.31%
2023-06-30 AU$164.63 Million +31.12%
2022-06-30 AU$125.56 Million +27.16%
2021-06-30 AU$98.74 Million +37.01%
2020-06-30 AU$72.07 Million +26.04%
2019-06-30 AU$57.18 Million +45.07%
2018-06-30 AU$39.42 Million +54.91%
2017-06-30 AU$25.44 Million +42.67%
2016-06-30 AU$17.83 Million +59.16%
2015-06-30 AU$11.21 Million -27.37%
2014-06-30 AU$15.43 Million +11.48%
2013-06-30 AU$13.84 Million +1.48%
2012-06-30 AU$13.64 Million -16.89%
2011-06-30 AU$16.41 Million -37.91%
2010-06-30 AU$26.43 Million -28.68%
2009-06-30 AU$37.05 Million -28.49%
2008-06-30 AU$51.81 Million -20.76%
2007-06-30 AU$65.39 Million +367.46%
2006-06-30 AU$13.99 Million +87.66%
2005-06-30 AU$7.45 Million -15.81%
2004-06-30 AU$8.85 Million +17.58%
2003-06-30 AU$7.53 Million -26.95%
2002-06-30 AU$10.31 Million -23.35%
2001-06-30 AU$13.45 Million -12.19%
2000-06-30 AU$15.32 Million --

Equity Component Analysis

This analysis shows how different components contribute to Clinuvel Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 6400627600.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Retained Earnings AU$63.63 Million 26.42%
Common Stock AU$169.28 Million 70.30%
Other Comprehensive Income AU$7.90 Million 3.28%
Total Equity AU$240.81 Million 100.00%

Clinuvel Pharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Clinuvel Pharmaceuticals Ltd ranked by their market capitalization.

Company Market Cap
Bk Harda Internasional Tbk Pt
JK:BBHI
 		$251.65 Million
Oceania Healthcare Ltd
AU:OCA
 		$251.67 Million
Woori Technology Investment Co. Ltd
KQ:041190
 		$251.72 Million
Shenzhen Xunjiexing Technology Corp. Ltd.
SHG:688655
 		$251.82 Million
Shandong Chenming Paper Holdings Ltd Class B
SHE:200488
 		$251.60 Million
Nanjing Textiles Import & Export Corp Ltd
SHG:600250
 		$251.60 Million
Jiangsu Sanfangxiang Industry Co Ltd
SHG:600370
 		$251.57 Million
TELUS International (Cda) Inc.
MU:5Z9
 		$251.53 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Clinuvel Pharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 203,011,366 to 240,808,626, a change of 37,797,260 (18.6%).
  • Net income of 36,172,518 contributed positively to equity growth.
  • Dividend payments of 2,504,019 reduced retained earnings.
  • Share repurchases of 440,906 reduced equity.
  • New share issuances of 189,000 increased equity.
  • Other comprehensive income increased equity by 3,650,461.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$36.17 Million +15.02%
Dividends Paid AU$2.50 Million -1.04%
Share Repurchases AU$440.91K -0.18%
Share Issuances AU$189.00K +0.08%
Other Comprehensive Income AU$3.65 Million +1.52%
Other Changes AU$730.21K +0.3%
Total Change AU$- 18.62%

Book Value vs Market Value Analysis

This analysis compares Clinuvel Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.04x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 5.75x to 2.04x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2000-06-30 AU$1.70 AU$9.75 x
2001-06-30 AU$1.88 AU$9.75 x
2002-06-30 AU$1.14 AU$9.75 x
2003-06-30 AU$0.83 AU$9.75 x
2004-06-30 AU$0.77 AU$9.75 x
2005-06-30 AU$0.57 AU$9.75 x
2006-06-30 AU$0.83 AU$9.75 x
2007-06-30 AU$2.63 AU$9.75 x
2008-06-30 AU$1.71 AU$9.75 x
2009-06-30 AU$1.22 AU$9.75 x
2010-06-30 AU$0.87 AU$9.75 x
2011-06-30 AU$0.54 AU$9.75 x
2012-06-30 AU$0.44 AU$9.75 x
2013-06-30 AU$0.39 AU$9.75 x
2014-06-30 AU$0.40 AU$9.75 x
2015-06-30 AU$0.26 AU$9.75 x
2016-06-30 AU$0.39 AU$9.75 x
2017-06-30 AU$0.51 AU$9.75 x
2018-06-30 AU$0.79 AU$9.75 x
2019-06-30 AU$1.15 AU$9.75 x
2020-06-30 AU$1.43 AU$9.75 x
2021-06-30 AU$1.93 AU$9.75 x
2022-06-30 AU$2.43 AU$9.75 x
2023-06-30 AU$3.18 AU$9.75 x
2024-06-30 AU$3.98 AU$9.75 x
2025-06-30 AU$4.78 AU$9.75 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Clinuvel Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 15.02%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 38.07%
  • • Asset Turnover: 0.35x
  • • Equity Multiplier: 1.13x
  • Recent ROE (15.02%) is above the historical average (-26.39%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 -11.58% -380.93% 0.03x 1.02x AU$-2.90 Million
2002 -30.47% -1217.44% 0.02x 1.02x AU$-4.17 Million
2003 -52.81% -2924.10% 0.02x 1.07x AU$-4.73 Million
2004 -85.72% -2137.95% 0.03x 1.16x AU$-8.48 Million
2005 -147.96% -8849.99% 0.01x 1.35x AU$-11.77 Million
2006 -76.98% -1426.65% 0.04x 1.22x AU$-12.17 Million
2007 -14.03% -3238.92% 0.00x 1.04x AU$-15.72 Million
2008 -28.29% -341.07% 0.08x 1.06x AU$-19.84 Million
2009 -41.49% -529.19% 0.07x 1.12x AU$-19.08 Million
2010 -43.60% -781.62% 0.05x 1.12x AU$-14.16 Million
2011 -69.53% -1095.95% 0.05x 1.23x AU$-13.05 Million
2012 -71.62% -1351.30% 0.05x 1.17x AU$-11.13 Million
2013 -49.16% -438.04% 0.10x 1.14x AU$-8.19 Million
2014 -35.82% -207.50% 0.16x 1.11x AU$-7.07 Million
2015 -92.66% -313.41% 0.24x 1.22x AU$-11.52 Million
2016 -17.54% -45.76% 0.34x 1.13x AU$-4.90 Million
2017 28.29% 42.83% 0.59x 1.13x AU$4.64 Million
2018 33.55% 51.89% 0.59x 1.09x AU$9.28 Million
2019 31.71% 58.41% 0.50x 1.09x AU$12.42 Million
2020 23.10% 51.12% 0.40x 1.13x AU$9.44 Million
2021 25.04% 51.54% 0.44x 1.10x AU$14.85 Million
2022 16.63% 31.77% 0.45x 1.15x AU$8.32 Million
2023 18.59% 39.08% 0.40x 1.18x AU$14.14 Million
2024 17.55% 40.41% 0.38x 1.14x AU$15.34 Million
2025 15.02% 38.07% 0.35x 1.13x AU$12.09 Million

Industry Comparison

This section compares Clinuvel Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $8,594,240
  • Average return on equity (ROE) among peers: -69.27%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Clinuvel Pharmaceuticals Ltd (CUV) AU$249.02 Million -11.58% 0.08x $251.65 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
ACRUX Ltd (ACR) $17.49 Million -17.99% 0.05x $2.16 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
Bio-Gene Technology Ltd (BGT) $4.25 Million -56.43% 0.18x $2.33 Million
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Cambium Bio Ltd (CMB) $8.27 Million -79.86% 0.16x $8.11 Million